Design and analysis of group sequential clinical trials with multiple primary endpoints

被引:24
|
作者
Kosorok, MR [1 ]
Shi, YJ [1 ]
DeMets, DL [1 ]
机构
[1] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53792 USA
关键词
alpha-spending function; beta-spending function; multivariate outcomes; sample size; time-to-event data;
D O I
10.1111/j.0006-341X.2004.00146.x
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In many phase III clinical trials, it is desirable to separately assess the treatment effect on two or more primary endpoints. Consider the MERIT-HF study, where two endpoints of primary interest were tune to death and the earliest of time to first hospitalization or death (The International Steering Committee on Behalf of the MERIT-HF Study Group, 1997, American Journal of Cardiology 80[9B], 54J-58J). It is possible that treatment has no effect on death but a beneficial effect on first hospitalization time, or it has a detrimental effect on death but no effect on hospitalization. A good clinical trial design should permit early stopping as soon as the treatment effect on both endpoints becomes clear. Previous work in this area has not resolved how to stop the study early when one or more endpoints have no treatment effect or how to assess and control the many possible error rates for concluding wrong hypotheses. In this article, we develop a general methodology for group sequential clinical trials with multiple primary endpoints. This method uses a global alpha-spending function to control the overall type I error and a multiple decision rule to control error rates for concluding wrong alternative hypotheses. The method is demonstrated with two simulated examples based on the MERIT-HF study.
引用
收藏
页码:134 / 145
页数:12
相关论文
共 50 条
  • [1] DESIGN OF GROUP SEQUENTIAL CLINICAL-TRIALS WITH MULTIPLE ENDPOINTS
    TANG, DI
    GNECCO, C
    GELLER, NL
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1989, 84 (407) : 776 - 779
  • [2] Defining information fractions in group sequential clinical trials with multiple endpoints
    Xu, Tu
    Qin, Qin
    Wang, Xin
    [J]. CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2018, 10 : 77 - 79
  • [3] Closed testing procedures for group sequential clinical trials with multiple endpoints
    Tang, DI
    Geller, NL
    [J]. BIOMETRICS, 1999, 55 (04) : 1188 - 1192
  • [4] Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials
    Hung, H. M. James
    Wang, Sue-Jane
    O'Neill, Robert
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2007, 17 (06) : 1201 - 1210
  • [5] Some Multiplicity Adjustment Procedures for Clinical Trials with Sequential Design and Multiple Endpoints
    Luo, Xiaodong
    Quan, Hui
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2024, 16 (01): : 104 - 115
  • [6] Group sequential designs for clinical trials with bivariate endpoints
    Hu, Junxiao
    Blatchford, Patrick J.
    Goldenberg, Neil A.
    Kittelson, John M.
    [J]. STATISTICS IN MEDICINE, 2020, 39 (26) : 3823 - 3839
  • [7] Sequential monitoring of clinical trials with multiple survival endpoints
    Williams, PL
    [J]. STATISTICS IN MEDICINE, 1996, 15 (21-22) : 2341 - 2357
  • [8] A group sequential Holm procedure with multiple primary endpoints
    Ye, Yining
    Li, Ai
    Liu, Lingyun
    Yao, Bin
    [J]. STATISTICS IN MEDICINE, 2013, 32 (07) : 1112 - 1124
  • [9] Hierarchical testing of multiple endpoints in group-sequential trials
    Glimm, Ekkehard
    Maurer, Willi
    Bretz, Frank
    [J]. STATISTICS IN MEDICINE, 2010, 29 (02) : 219 - 228
  • [10] Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints
    Asakura, Koko
    Hamasaki, Toshimitsu
    Evans, Scott R.
    [J]. BIOMETRICAL JOURNAL, 2017, 59 (04) : 703 - 731